• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Acurx Pharmaceuticals Inc.

    4/29/24 4:12:07 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email
    DEFA14A 1 tm242861d4_defa14a.htm DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.)

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material Under Rule 14a-12

     

    ACURX PHARMACEUTICALS, INC.

     

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.

     

    ¨Fee previously paid with preliminary materials.

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V46475-P09238 ACURX PHARMACEUTICALS, INC. 259 LIBERTY AVENUE STATEN ISLAND, NY 10305 ACURX PHARMACEUTICALS, INC. 2024 Annual Meeting Vote by June 16, 2024 11:59 PM ET You invested in ACURX PHARMACEUTICALS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 17, 2024. Vote Virtually at the Meeting* June 17, 2024 10:00 AM EDT Virtually at: www.virtualshareholdermeeting.com/ACXP2024 Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 3, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

     

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V46476-P09238 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Directors Nominees: 1a. Robert J. DeLuccia For 1b. James Donohue For 1c. Joseph C. Scodari For 2. Proposal to ratify the appointment of CohnReznick LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2024. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

     

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP

    DatePrice TargetRatingAnalyst
    11/29/2021$12.00Buy
    Maxim Group
    More analyst ratings

    $ACXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:32:30 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:59 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:33 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    SEC Filings

    View All

    SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.

    EFFECT - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    2/12/26 12:15:18 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.

    424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    2/11/26 4:21:38 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Acurx Pharmaceuticals Inc.

    S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    2/2/26 4:48:05 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Shawah Robert G.

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:47:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Luci David P

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:46:58 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Deluccia Robert J

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    2/6/25 5:45:47 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

    STATEN ISLAND, N.Y., Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the United States Patent and Trademark Office has granted a new U.S. patent, US 12,534,470. This latest patent, which covers DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, further strengthens Acurx's intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx h

    2/2/26 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

    The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the modes of DNA polymerase pol IIIC (PolC) action and resistance are conserved across important species of Gram-positive multidrug resistant organismsThe previous LUMC-Acurx Health~Holland project successfully elucidated the structure of PolC from E. faecium, a critical Gram-positive human pathogen, in complex with two Acurx pol IIIC inhibitors. These data, using both Acrux's Phase 3-ready ibezapolstat for treatment of C. difficile infection and an advanced preclinical pol IIIC inhibitor from the ong

    11/18/25 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.   Highlights of the third quarter ended September 30, 2025, or in some cases shortly thereafter, include: On August 4, 2025, we effected a 1-for-20 reverse stock split of our issued and outstanding shares of common stock, and as a result of the reverse-stock-split, on August 26, 2025, we regained compliance with the minimum bid price requirement of

    11/12/25 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

    Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    11/29/21 8:33:36 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.   Highlights of the third quarter ended September 30, 2025, or in some cases shortly thereafter, include: On August 4, 2025, we effected a 1-for-20 reverse stock split of our issued and outstanding shares of common stock, and as a result of the reverse-stock-split, on August 26, 2025, we regained compliance with the minimum bid price requirement of

    11/12/25 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2025 financial results on Wednesday, November 12, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date:                           Wednesday, November 12, 2025 Time:                       

    10/27/25 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., Aug. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2025.   Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, we announced that the Indian Patent Office granted a new patent for our DNA polymerase IIIC inhibitors which expires in December 2039, subject to extension. This constitutes another significant building block for our ongoing preclinical antib

    8/12/25 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/24 2:39:21 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/23 11:59:03 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

    SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

    2/14/23 11:52:45 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care